MedTrace Logo

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

NCT05908786 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2025-12-11

No results posted yet for this study

Summary

This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC. The study is designed with the flexibility to open new treatment arms as new agents become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

Atezolizumab

Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.

DRUG

Bevacizumab

Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.

DRUG

Tiragolumab

Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.

DRUG

Tobemstomig

Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-05
Primary Completion
2025-08-27
Completion
2025-11-13
FDA Drug
Yes

Countries

  • United States
  • Austria
  • France
  • Germany
  • New Zealand
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05908786 on ClinicalTrials.gov